validation verification
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613
21 July 2011
EMEA/CHMP/EWP/192217/2009 Committee for Medicinal Products for Human Use (CHMP)
Guideline on bioanalytical method validation
Draft agreed by the Efficacy Working Party
September 2009 Adoption by CHMP for release for consultation 19 November 2009 End of consultation (deadline for comments)
31 May 2010 Agreed by Pharmacokinetics Working Party (PKWP)
June 2011 Adoption by CHMP
21 July 2011 Date for coming into effect
1 February 2012
Keywords CHMP, EMEA, Guideline, validation, bioanalytical method, analyses
Guideline on bioanalytical method validation
Table of contents
1. Introduction (background) (3)
2. Scope (3)
3. Legal basis (3)
4. Method validation (4)
4.1. Full validation of an analytical method (4)
4.1.1. Selectivity (5)
4.1.2. Carry-over (5)
4.1.3. Lower limit of quantification (6)
4.1.4. Calibration curve (6)
4.1.5. Accuracy (7)
4.1.6. Precision (7)
4.1.7. Dilution integrity (8)
4.1.8. Matrix effect (8)
4.1.9. Stability (9)
4.2. Partial validation (10)
4.3. Cross validation (10)
5. Analysis of study samples (10)
5.1. Analytical run (11)
5.2. Acceptance criteria of an analytical run (11)
5.3. Calibration range (12)
5.4. Reanalysis of study samples (12)
5.5. Integration (13)
6. Incurred samples reanalysis (13)
7. Ligand binding assays (14)
7.1.1. Full validation (14)
7.2. Partial validation and cross-validation (17)
7.3. Analysis of study samples (17)
7.3.1. Analytical run (17)
7.3.2. .Acceptance criteria for study sample analysis (17)
7.3.3. Incurred samples reanalysis (18)
8. Reports (18)
8.1. Validation report (18)
8.2. Analytical report (19)
Definitions (20)
Executive summary
This guideline defines key elements necessary for the validation of bioanalytical methods. The guidelin
e focuses on the validation of the bioanalytical methods generating quantitative concentration data used for pharmacokinetic and toxicokinetic parameter determinations. Guidance and criteria are given on the application of these validated methods in the routine analysis of study samples from animal and human studies.
1. Introduction (background)
Measurement of drug concentrations in biological matrices (such as serum, plasma, blood, urine, and saliva) is an important aspect of medicinal product development. Such data may be required to support applications for new actives substances and generics as well as variations to authorised drug products. The results of animal toxicokinetic studies and of clinical trials, including bioequivalence studies are used to make critical decisions supporting the safety and efficacy of a medicinal drug substance or product. It is therefore paramount that the applied bioanalytical methods used are well characterised, fully validated and documented to a satisfactory standard in order to yield reliable results.
Acceptance criteria wider than those defined in this guideline may be used in special situations. This should be prospectively defined based on the intended use of the method.
2. Scope
This guideline provides recommendations for the validation of bioanalytical methods applied to measure drug concentrations in biological matrices obtained in animal toxicokinetic studies and all phases of clinical trials. As ligand binding assays differ substantially from chromatographic analytical methods, separate validation recommendations for ligand binding assays are provided.
In addition, specific aspects for the analysis of study samples will be addressed.
Furthermore, this guideline will describe when partial validation or cross validation should be carried out in addition to the full validation of an analytical method.
Methods used for determining quantitative concentrations of biomarkers used in assessing pharmacodynamic endpoints are out of the scope of this guideline.
3. Legal basis
This guideline has to be read in conjunction with the introduction and general principles (4) and Part I and II of the Annex I to Directive 2001/83 as amended. It applies to Marketing Authorisation Applications for human medicinal products submitted in accordance with the Directive 2001/83/EC as
amended, and Regulation (EC) No. 726/2004, in which the analysis of drug concentrations in a biological matrix is part of the application.
The validation of bioanalytical methods and the analysis of study samples for clinical trials in humans should be performed following the principles of Good Clinical Practice (GCP). Further guidance that will help clinical laboratories develop and maintain quality systems which will comply with relevant European Union Directives, national regulations and associated guidance documents can be found in the “Reflection Paper for Laboratories That Perform The Analysis Or Evaluation Of Clinical Trial Samples.” (EMA/INS/GCP/532137/2010).
Non-clinical (pharmaco-toxicological) studies submitted in a marketing authorisation application shall be carried out in conformity with the provisions related to Good Laboratory Practice, Directive
2004/10/EC on the harmonisation of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances and Directive 2004/9/EC on the inspection and verification of good laboratory practice (GLP). Normally, the validation of bioanalytical methods used in non-clinical pharmacotoxicological studies that are carried out in conformity with the provisions related to Good La
boratory Practice should be performed following the Principles of Good Laboratory Practice.  Aspects of method validation not performed according to GLP should be clearly identified and their potential impact on the validation status of the method indicated. Methods used in pre-clinical studies not required to be performed to GLP should be fit for purpose but not necessarily developed in a GLP facility.
4. Method validation
4.1. Full validation of an analytical method
A full method validation should be performed for any analytical method whether new or based upon literature.
The main objective of method validation is to demonstrate the reliability of a particular method for the determination of an analyte concentration in a specific biological matrix, such as blood, serum, plasma, urine, or saliva. Moreover, if an anticoagulant is used, validation should be performed using the same anticoagulant as for the study samples. Generally a full validation should be performed for each species and matrix concerned.
In some cases, it may be problematic for validation purposes to obtain an identical matrix compared to the matrix of the study samples. A suitable alternative matrix may be used, e.g. synthetically prepared cerebrospinal fluid, if justified.
The main characteristics of a bioanalytical method that are essential to ensure the acceptability of the performance and the reliability of analytical results are: selectivity, lower limit of quantification, the response function and calibration range (calibration curve performance), accuracy, precision, matrix effects, stability of the analyte(s) in the biological matrix and stability of the analyte(s) and of the internal standard in the stock and working solutions and in extracts under the entire period of storage and processing conditions.
Usually one analyte or drug has to be determined, but on occasions it may be appropriate to measure more than one analyte. This may involve two different drugs, but can also involve a parent drug with its metabolites, or the enantiomers or isomers of a drug. In these cases the principles of validation and analysis apply to all analytes of interest.
Reference standards
During method validation and analysis of study samples, a blank biological matrix will be spiked with th
e analyte(s) of interest using solutions of reference standard(s) to prepare calibration standards, quality control samples and stability samples. In addition, suitable internal standard(s) (IS) can be added during sample processing in chromatographic methods.
It is important that the quality of the reference standard and IS is ensured, as the quality (purity) may affect the outcome of the analysis, and therefore the outcome of the study data. Therefore the reference standards used during the validation and study sample analysis should be obtained from an authentic and traceable source. Suitable reference standards, include certified standards such as
compendial standards (EPCRS, USP, WHO), commercially available standards, or sufficiently characterised standards prepared in-house or by an external non-commercial organisation. A certificate of analysis is required to ensure purity and provide information on storage conditions, expiration date and batch number of the reference standard.
The use of certified standards is not needed for IS, as long as the suitability for use is demonstrated, e.g. lack of analytical interference is shown for the substance itself or any impurities thereof. A certificate of analysis is not required.
When mass-spectrometry (MS) detection is used in the bioanalytical method, a stable isotope-labelled
IS is recommended to be used whenever possible. However, it is essential that the labelled standard is of the highest isotope purity and that no isotope exchange reaction occurs. The presence of any unlabelled analyte should be checked and if relative amounts of unlabelled analyte are detected the potential influence has to be evaluated during method validation.
4.1.1. Selectivity
The analytical method should be able to differentiate the analyte(s) of interest and IS from endogenous components in the matrix or other components in the sample. Selectivity should be proved using at least 6 individual sources of the appropriate blank matrix, which are individually analysed and evaluated for interference. Use of fewer sources is acceptable in case of rare matrices. Normally, absence of interfering components is accepted where the response is less than 20% of the lower limit of quantification for the analyte and 5% for the internal standard.
It may also be necessary to investigate the extent of any interference caused by metabolites of the drug(s), interference from degradation products formed during sample preparation, and interference from possible co-administered medications. Co-medications normally used in the subject population studied which may potentially interfere should be taken into account at the stage of method validation, or on a study specific and compound specific base.
The possibility of back-conversion of a metabolite into parent analyte during the successive steps of the analysis (including extraction procedures or in the MS source) should also be evaluated, when relevant (i.e. potentially unstable acidic metabolites to ester, unstable N-oxides or glucuronide metabolites, lactone-ring structures). The extent of back-conversion should be established and the impact on the study results discussed. It is acknowledged that this evaluation will not be possible early during drug development of a new chemical entity when the metabolism is not yet evaluated. However, it is expected that this issue is taken into account and a partial validation is performed if relevant as further knowledge regarding metabolism of the active substance is gained during drug development.
It is recognized that in some cases it is very difficult to obtain the metabolites of interest. Alternatively, back-conversion of a metabolite can be checked by applying incurred sample reanalysis. However, in this case potential back conversion during sample processing cannot be ruled out.
4.1.2. Carry-over
Carry-over should be addressed and minimised during method development. During validation carry-over should be assessed by injecting blank samples after a high concentration sample or calibration st
andard at the upper limit of quantification. Carry over in the blank sample following the high concentration standard should not be greater than 20% of the lower limit of quantification (LLOQ; see below) and 5% for the internal standard. If it appears that carry-over is unavoidable, study samples should not be randomised. Specific measures should be considered, tested during the validation and

版权声明：本站内容均来自互联网，仅供演示用，请勿用于商业和其他非法用途。如果侵犯了您的权益请与我们联系QQ:729038198，我们将在24小时内删除。